Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX3397 in KIT-mutated advanced acral and mucosal melanoma
2013-002073-22Phase 2Unknown
- Sponsor
- The Christie
- Start
- Jun 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pexidartinib in melanoma, mucosal melanoma (MM) and acral lentiginous melanoma (ALM), sponsored by The Christie. Primary endpoints: Progression-free survival at 6 months and Overall survival rate. Status: unknown.
02
Drugs
pexidartinib
03
Conditions
melanomamucosal melanoma (MM)acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on 2013-002073-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002073-22.